

Jense Panse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/629904/publications.pdf>

Version: 2024-02-01

60
papers

2,114
citations

304743

22
h-index

243625

44
g-index

63
all docs

63
docs citations

63
times ranked

2978
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	7.2	29
2	Antibody titers after SARS-CoV-2 mRNA vaccination in patients with aplastic anemia—A single-center study. <i>European Journal of Haematology</i> , 2022, 108, 528-531.	2.2	4
3	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
4	Imaging patterns of cerebral ischemia in hypereosinophilic syndrome: case report and systematic review. <i>Neurological Sciences</i> , 2022, , .	1.9	0
5	Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita. <i>British Journal of Haematology</i> , 2021, 193, 669-673.	2.5	20
6	Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 572-582.	1.1	38
7	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	10.0	26
8	Internet-based patient survey on the consequences of COVID-19 lockdown on treatment and medical follow-up of patients with aplastic anemia or paroxysmal nocturnal hemoglobinuria in Germany. <i>European Journal of Haematology</i> , 2021, 106, 740-742.	2.2	0
9	Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. <i>Blood</i> , 2021, 137, 2070-2084.	1.4	21
10	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	3.8	13
11	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 3965-3976.	2.4	6
12	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.7	14
13	Comprehensive support for families with parental cancer (Family-SCOUT), evaluation of a complex intervention: study protocol for a non-randomized controlled trial. <i>Trials</i> , 2021, 22, 622.	1.6	7
14	Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101560.	0.4	7
15	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , 2021, 27, 2192-2199.	30.7	79
16	Central venous catheter-related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a randomized controlled trial. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1-3.	1.8	9
17	Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies. <i>Annals of the New York Academy of Sciences</i> , 2020, 1466, 93-103.	3.8	35
18	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34

#	ARTICLE	IF	CITATIONS
19	Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7196.	4.1	18
20	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3121-3127.e1.	3.8	28
21	CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. <i>Nature Communications</i> , 2020, 11, 798.	12.8	43
22	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
23	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2020, 135, 912-920.	1.4	73
24	Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 35-37.	1.4	2
25	YIA20-003: CD229 CAR T Cells Eliminate Multiple Myeloma and Tumor Propagating Cells but Show Limited Targeting of Normal T Cells. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, YIA20-003.	4.9	0
26	Pulmonary infections in patients with and without hematological malignancies: diagnostic yield and safety of flexible bronchoscopy-a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2020, 12, 4860-4867.	1.4	0
27	An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial. <i>Blood</i> , 2020, 136, 2-3.	1.4	2
28	Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
29	COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 6-7.	1.4	1
30	Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab. <i>Blood</i> , 2020, 136, 10-12.	1.4	8
31	Impact of neutropenia on central venous catheter-related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1204-1206.	1.8	7
32	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	4.6	101
33	Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH) – a report on phase III. <i>Annals of Hematology</i> , 2019, 98, 1547-1559.	1.8	18
34	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
35	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	1.8	162
36	Leukocyte Counts Based on DNA Methylation at Individual Cytosines. <i>Clinical Chemistry</i> , 2018, 64, 566-575.	3.2	21

#	ARTICLE	IF	CITATIONS
37	Questionnaires measuring quality of life and satisfaction of patients and their relatives in a palliative care settingâ€”German translation of FAMCARE-2 and the palliative care subscale of FACIT-Pal. <i>Annals of Palliative Medicine</i> , 2018, 7, 420-426.	1.2	15
38	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 2116-2127.	13.7	79
39	Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)â€”report on phases I and II. <i>Annals of Hematology</i> , 2017, 96, 171-181.	1.8	25
40	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e510-e523.	4.6	258
41	Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. <i>Annals of Hematology</i> , 2017, 96, 1463-1470.	1.8	48
42	A three-gene expression-based risk score can refine the European LeukemiaNet AML classification. <i>Journal of Hematology and Oncology</i> , 2016, 9, 78.	17.0	21
43	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e217-e227.	4.6	442
44	Pharmacological treatment options for mast cell activation disease. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 671-694.	3.0	53
45	Health-related quality of life in patients with indolent and aggressive non-Hodgkin lymphoma. <i>Cogent Psychology</i> , 2016, 3, 1169582.	1.3	1
46	Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph+ leukemia. <i>Experimental Hematology and Oncology</i> , 2015, 5, 5.	5.0	1
47	Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. <i>Leukemia Research</i> , 2015, 39, 1292-1298.	0.8	15
48	Drugging the unfolded protein response in acute leukemias. <i>Journal of Hematology and Oncology</i> , 2015, 8, 87.	17.0	22
49	Key role of MIF in the migration of endothelial progenitor cells in patients during cardiac surgery. <i>International Journal of Cardiology</i> , 2015, 181, 284-287.	1.7	5
50	<i>PIK3CA</i> mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies. <i>Oncotarget</i> , 2015, 6, 1315-1326.	1.8	105
51	Comorbidity Scales in Patients with Myeloproliferative Neoplasms: Which One Fits Best?. <i>Blood</i> , 2014, 124, 1828-1828.	1.4	3
52	Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02). <i>Blood</i> , 2014, 124, 798-798.	1.4	31
53	Development Of a Disease Specific Quality Of Life Questionnaire For Patients With Aplastic Anemia and/Or Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/PNH). <i>Blood</i> , 2013, 122, 1680-1680.	1.4	2
54	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. <i>Blood</i> , 2012, 120, 302-302.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Identification of Atypical Plasma Cells in Patients with MGUS or Multiple Myeloma Through Expression of Immunoreceptor CD229. <i>Blood</i> , 2012, 120, 4969-4969.	1.4	0
56	Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) in Germany: A Retrospective Multicenter Case Study of 29 Patients. <i>Blood</i> , 2012, 120, 3271-3271.	1.4	5
57	Accelerated Telomere Shortening Identifies a Subgroup of Patients with Myelodysplastic Syndrome and Isolated 5q Minus Deletion with a Higher Probability of Response to Lenalidomide Treatment. <i>Blood</i> , 2012, 120, 3809-3809.	1.4	0
58	Empfehlungen zur Diagnostik der Paroxysmalen nchtlichen Hmoglobinurie: deutsch sterreichischer Konsensus/Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian consensus. <i>Laboratoriums Medizin</i> , 2011, 35, 315-327.	0.6	2
59	Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,. <i>Blood</i> , 2011, 118, 3427-3427.	1.4	0
60	Empirical Vs. Prophylactic Antifungal Strategies: Comparison of Effectiveness In High Risk AML Patients at a Tertiary Cancer Center. <i>Blood</i> , 2010, 116, 1729-1729.	1.4	0